|
Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
| 2022. szeptember 8., csütörtök 09:23 |
ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS (part 1) |
|
| Lausanne, Switzerland, 8 September, 2022 (APA/OTS) - International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics - The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly address the threat of AMR - Debiopharm will join the action-focused discussions around this silent pandemic in 3 panel discussions, presenting their microbiome-sparing FabI inhibitor class as a future tool to fight AMR |
Debiopharm, (www.debiopharm.com) a privately-owned, Swiss-based,
biopharmaceutical company committed to the development of novel
class antibiotics, today revealed its involvement in three panel
discussions at the World AMR Congress, taking place in Fort
Washington, Maryland, from September 7th - 8th. This conference
offers pharmaceutical companies, government, and policy stakeholders
from all around the world the opportunity to meet, discuss and
formulate initiatives to effectively tackle the emerging threat of
antimicrobial resistance. Debiopharm will present developments on
its FabI inhibitor antibiotic class including afabicin (Debio 1450),
Debio 1453 and Debio 1454S, all of which have microbiome-sparing
potential, a promising characteristic for AMR prevention.
AMR is a leading cause of death and disability and represents a
major threat to human health. Among the 1.27 million deaths [1] that
occur globally due to antibiotic-resistant infections each year,
more than 35,000 [2] occur in the United States and over 33, [3]
occur in Europe. The economic burden of AMR is also significant [4]
in direct health care and lost productivity costs are attributable
to antibiotic-resistant bacteria like Staphylococcus spp.
The WHO and the CDC have identified such pathogens posing a threat
to public health and Debiopharm, one of the few private companies
still engaged in the development of novel antibiotics, has directed
its efforts toward targeting them. The World AMR summit offers a
great opportunity to governments, funds, associations, and
passionate companies like Debiopharm to join forces against one of
the top global public threats facing humanity.
"We're proud to unveil more on the role our novel class antibiotic,
the FabI inhibitors, amongst key international stakeholders at the
World AMR. We're hoping that our collaboration with specialized
organizations and lawmakers will trigger the much needed changes in
the way we think about the unmet need for antibiotics as well as
provide hope to people and health practitioners dealing with these
seemingly insurmountable infections" stated Mohammed Benghezal,
Global Project Lead in Anti-infectives, Debiopharm.
"Pathogen-specific antibiotic effect without harming the "good" gut
bacteria: it is the best of both worlds! As we research their
efficacy and safety profile, this class of antibiotics could be like
no other," expressed Ricardo Chaves, Executive Medical Director,
Debiopharm. "Now is the time to encourage the development of new
antibiotic classes by establishing new business models that will
assure future patients access to effective treatments that will
knock out highly resistant bacterial infections and at the same time
prevent AMR development."
World AMR 2022 Congress agenda Speakers
Session Details
================ ======================= ======================================
Session 1 - Disease Prevention & Ricardo Chaves, Executive Medical
Sept.7th, Control Summit – Director, Debiopharm + other invited
Keynote panel Funding & Commercial speakers
discussion, Landscape
09:40 – 10:20
EST
---------------- ----------------------- --------------------------------------
Session 2 - Antibiotic Development Ricardo Chaves, Executive Medical
Sept.7th, – Panel Discussion / Director, Debiopharm; Vance Fowler,
11:40-12:10 EST Pathogen-specific Professor of Medicine, c and
antibiotic therapy: A Microbiology, Duke University, North
new paradigm to face Carolina; James Anderson, Executive
AMR? Director Global Health, IFPMA
---------------- ----------------------- --------------------------------------
Session 3 - Innovation Showcase - Riccardo Nisato, Licensing and Grant
Sept.8th, Microbiome / One Drug Associate Manager, Debiopharm;
11:40-12:00 EST for One Bug: FabI Novel Mohammed Benghezal, Global Project
Class Antibiotics for Lead in Anti-infectives, Debiopharm
Microbiome Sparing and
AMR Prevention
---------------- ----------------------- --------------------------------------
|
|
|
|
|
|
|
| 2022. szeptember 8., csütörtök 09:23 |
ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS (part 2) |
|
| Lausanne, Switzerland, 8 September, 2022 (APA/OTS) - |
About afabicin
Afabicin (Debio 1450) is Debiopharm's first-in-class FabI inhibitor
against Staphylococcus spp., whose sub-class Methicillin-resistant
Staphylococcus aureus (MRSA) is high on the WHO global priority
pathogen list and deemed a "serious threat" by the CDC. Afabicin can
be administered orally or IV and selectively targets Staphylococcus'
essential bacterial fatty acid biosynthesis. Promising results have
been obtained in a comparative double-blind Phase 2 trial with
afabicin in acute bacterial skin and skin structure infections.
Currently, an international Phase 2 trial in bone and joint
infections is being conducted comparing afabicin to standard
antibiotics.
About Debio 1453 and Debio 1454S
Analogous to Afabicin, the preclinical compounds Debio 1453 and
Debio 1454S are potential first in class pathogen-specific drugs
targeting the essential bacterial fatty acid biosynthesis. Debio
1453 can be administered orally or intramuscularly to treat
Neisseria gonorrhoeae infections while Debio 1454S is being
developed for IV use in cases of hospital-acquired pneumonia and
ventilator-associated pneumonia caused by carbapenem-resistant
Acinetobacter baumannii.
Debiopharm's fight against antimicrobial resistance
Debiopharm, an innovation-focused, Swiss biopharmaceutical company
is one of the few privately owned companies developing novel class
antibiotics to combat hard-to-treat infections. Through their unique
partnership-based business model, the company is advancing
pathogen-specific antibiotics from early stage through phase II
clinical research with afabicin, specifically targeting
staphylococci, being the most clinically advanced for the treatment
of bone and joint infections. As a result of high selectivity, FabI
inhibitors specifically target selected pathogens while preserving
intestinal microbiota and meet all four WHO 2020 innovation
criteria: new chemical class, new target, new mode of action and no
cross-resistance to other antibiotic classes.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Haughton
Communication Manager
dawn.haughton@debiopharm.com
Tel: +41 (0)21 321 01 11
References
[1] Antimicrobial Resistance Collaborators. Global burden of
bacterial antimicrobial resistance in 2019: a systematic analysis.
Lancet. 2022;399(10325):629-655.
[2] CDC Antibiotic resistance threats in the United States, 2019.
https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
[3] Cassini A, et al. Attributable deaths and disability-adjusted
life-years caused by infections with antibiotic-resistant bacteria
in the EU and the European Economic Area in 2015: a population-level
modelling analysis. Lancet Infect Dis. 2019;19(1):56-66.
[4] CDC Antibiotic resistance threats in the United States, 2013.
https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|